Cost Comparison of Open and Arthroscopic Treatment Options for SLAP Tears

Osteoid osteoma (OO) apparent in the intra-articular region of the elbow is very rare. Although computed tomography-guided excision and radiofrequency ablation have been recognized as useful treatment options, arthroscopic excision has recently received focus as an alternative strategy for lesions close to neurovascular structures or intra- and juxta-articular lesions. We herein report a 17-year-old female who underwent arthroscopic treatment for intra-articular OO located at the olecranon/coronoid fossa. Her symptoms included elbow pain that was exacerbated at night and contracture of elbow flexion-extension, and she was diagnosed with intra-articular OO after 12 months of symptomatic history. Arthroscopically, thorough synovectomy for both the anterior and posterior aspects of the joint enabled definition of the tumor margin with hyperemic alteration and excision of the lesion as an en bloc specimen. At the 12-month follow-up, the patient had no recurrence of elbow limitation or pain. This case report describes the advantages of arthroscopic treatment, including a low-invasive approach and easy accessibility to the whole intra-articular space, which can provide clear visualization of the tumorous lesion.

Download Full-text

Women with Newly Diagnosed Uterine Fibroids: Treatment Patterns and Cost Comparison for Select Treatment Options

Population Health Management ◽

10.1089/pop.2017.0151 ◽

2018 ◽

Vol 21 (S1) ◽

pp. S-13-S-20 ◽

Cited By ~ 8

Author(s):

Machaon M. Bonafede ◽

Scott K. Pohlman ◽

Jeffrey D. Miller ◽

Ellen Thiel ◽

Kathleen A. Troeger ◽

...

Keyword(s):

Treatment Options ◽

Uterine Fibroids ◽

Treatment Patterns ◽

Cost Comparison ◽

Newly Diagnosed

Download Full-text

Cost Comparison of Benign Prostatic Hyperplasia Treatment Options

Current Urology Reports ◽

10.1007/s11934-019-0907-3 ◽

2019 ◽

Vol 20 (8) ◽

Cited By ~ 7

Author(s):

Molly E. DeWitt-Foy ◽

Bradley C. Gill ◽

James C. Ulchaker

Keyword(s):

Benign Prostatic Hyperplasia ◽

Treatment Options ◽

Prostatic Hyperplasia ◽

Cost Comparison

Download Full-text

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s34371 ◽

2012 ◽

pp. 237 ◽

Cited By ~ 8

Author(s):

Bjoern Schwander ◽

Ravera ◽

Giuliani ◽

Nuijten ◽

Stefan Walzer

Keyword(s):

Lung Cancer ◽

Cost Analysis ◽

Late Stage ◽

Treatment Options ◽

Small Cell ◽

Cost Comparison ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Cancer Cost

Download Full-text

Cost Comparison of Collagenase Clostridium Histolyticum and Fasciectomy for Treatment of Dupuytren’s Contracture in the Australian Health System

The Journal of Hand Surgery (Asian-Pacific Volume) ◽

10.1142/s2424835518500327 ◽

2018 ◽

Vol 23 (03) ◽

pp. 336-341 ◽

Cited By ~ 5

Author(s):

Andrew K. Sefton ◽

Belinda J. Smith ◽

David A. Stewart

Keyword(s):

Treatment Options ◽

Cost Comparison ◽

Dupuytren’S Disease ◽

Dupuytren’S Contracture ◽

Collagenase Clostridium Histolyticum ◽

Health Care Environment ◽

Dupuytren's Disease ◽

Australian Health ◽

Dupuytren's Contracture ◽

Clostridium Histolyticum

Background: Dupuytren’s disease results in contracted cords in the hand that lead to deformity and disability. Current treatment options include fasciectomy and an injectable, collagenase clostridium histolyticum. No cost comparison studies have been published within the Australian health care environment. Methods: A retrospective review of all patients treated for Dupuytren’s disease in a major teaching hospital was undertaken to compare the costs of treatment by fasciectomy or collagenase injection. Results: Eighteen patients underwent fasciectomy and 21 collagenase clostridium histolyticum injections were performed during the study period and were eligible for inclusion under the review criteria. Of the 39 patients, 36 were male and 3 were female with an average age 66.4 years (50–85). Twenty-five digits were treated by fasciectomy in 18 patients, and 23 digits were treated by collagenase in 21 patients. The fasciectomy group attended an average 9.2 visits (5–22), incurring an average costing of US$5738.12 per patient ($3181.18–$9618.10). The collagenase group attended an average 3.8 visits (3–8), incurring an average costing of US$2076.83 per patient ($1842.24–$3929.57). Conclusions: Collagenase treatment of Dupuytren’s contracture represents a significant reduction in cost relative to fasciectomy, with 64% savings, length of follow up and number of visits. This is a similar finding to studies in other countries.

Download Full-text

Choice of sequential biologic therapies in metastatic colorectal cancer (mCRC): A cost comparison analysis for wild-type KRAS mCRC patient population in Brazil.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e14679 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e14679-e14679

Author(s):

Rui Weschenfelder ◽

Caio Timko Buschinelli

Keyword(s):

Colorectal Cancer ◽

Treatment Options ◽

Drug Acquisition ◽

Cost Savings ◽

Cost Comparison ◽

Wild Type ◽

Payer Perspective ◽

Third Line ◽

Cost Comparison Analysis ◽

Entire Treatment

e14679 Background: Colorectal cancer is the third most common cancer and the second leading cause of cancer-related death in Brazil. Metastatic disease affects up to 50% of patients resulting in 5-year survival of less than 10%. Therefore, there is an increasing interest about the best treatment options, mainly regarding biologics and their sequencing across first line (1L) and second line (2L) treatment of mCRC. Modern series show that the probability of a patient receives 1L, 2L and a third line (3L) therapy is approximately 99%, 70% and 40%, respectively. In addition, in 2012, the ML 18147 study demonstrated the benefit of sequential use, 1L and 2L, of bevacizumab (bev) based combination in mCRC and considering this emerging data, it is important to understand the implications in terms of costs for the Brazilian private healthcare system. Methods: A costing tool was developed to compare the sequencing costs of 1L → 2L regimens used for treatment of wild-type KRAS mCRC patients. Dosing schedules were derived from labels, clinical trials and expert opinion. Analysis was performed from a private payer perspective and included drug-acquisition and administration costs only. Sequences in the ML18147 study (1L bev 5mg/kg+FOLFOX → 2L bev 5mg/kg+FOLFIRI and 1L bev 5mg/kg+FOLFIRI→2L bev 5mg/kg+FOLFOX) were compared to another frequently used sequence in Brazil where bev is replaced by cetuximab(cet) in 1L (1L cet 400-250mg/m2+ FOLFIRI → 2L bev 5 mg/Kg + FOLFOX). Results: Average costs per patient per month were Brz 21,285.50 for sequences with bev in 1L and 2L and Brz 24,191.68 when bev is replaced by cet in 1L. The average cost savings per patient for the entire treatment were Brz 28,767 (1L bev 5mg/kg + FOLFOX → 2L bev 5mg/kg + FOLFIRI vs 1L cet + FOLFIRI → 2L bev + FOLFOX) and Brz 29,938 (1L bev 5mg/kg + FOLFIRI → 2L bev 5mg/kg + FOLFOX vs1L cet + FOLFIRI → 2L bev + FOLFOX). Conclusions: Sequential use of bev in 1L and 2L mCRC according to the ML18147 study protocol is less costly compared to another sequence of biologics that starts with cet in 1L followed by bev in 2L. Resources savings with sequential bev have the potential to optimize 3L treatment strategy for wild-type kras mCRC patients in Brazil.

Download Full-text

Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-019-0191-6 ◽

2019 ◽

Vol 17 (1) ◽

Cited By ~ 2

Author(s):

Gilbert Spizzo ◽

Uwe Siebert ◽

Guenther Gastl ◽

Andreas Voss ◽

Klaus Schuster ◽

...

Keyword(s):

Advanced Cancer ◽

Treatment Cost ◽

Treatment Plan ◽

Treatment Options ◽

In Situ Hybridisation ◽

Treatment Decision ◽

Treatment Costs ◽

Cost Comparison ◽

Advanced Cancer Patients ◽

Tumor Profiling

Abstract Background Tumor profiling is increasingly used in advanced cancer patients to define treatment options, especially in refractory cases where no standard treatment is available. Caris Molecular Intelligence (CMI) is a multiplatform tumor profiling service that is comprehensive of next-generation sequencing (NGS) of DNA and RNA, immunohistochemistry (IHC) and in situ hybridisation (FISH). The aim of this study is to compare costs of CMI-guided treatment with prior or planned treatment options in correlation with outcome results. Methods Retrospective data from five clinical trials were collected to define the treatment decision prior to the receipt of the CMI report (n = 137 patients). A systematic review of treatment data from 11 clinical studies of CMI (n = 385 patients) allowed a comparison of planned vs actual (n = 137) and prior vs actual (n = 229) treatment costs. Results Treatment plan was changed in 88% of CMI-profiled cases. The actual CMI guided treatment cost per cycle was £995 in 385 treated patients. Planned treatment costs were comparable to actual treatment costs (£979 vs £945; p = 0.7123) and prior treatment costs were not significantly different to profiling-guided treatments (£892 vs £850; p = 0.631). Conclusions Caris Molecular Intelligence guided treatment cost per cycle was in the range of prior or planned treatment cost/cycle. Due to beneficial overall survival the additional cost of performing CMI’s multiplatform testing to the treatment costs seems to be cost-effective.

Download Full-text